Carisbamate, a new carbamate for the treatment of epilepsy

IDrugs

Volumn 10, Issue 10, 2007, Pages 720-727

  Kulig, K ^a   Malawska, B ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBAMIC ACID DERIVATIVE; CARISBAMATE; DIAZEPAM; FELBAMATE; KAINIC ACID; LAMOTRIGINE; LITHIUM; PILOCARPINE; PLACEBO; RWJ 333369A; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ABSENCE; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ATAXIA; BIPOLAR DISORDER; BRAIN EDEMA; BRAIN INJURY; CLINICAL TRIAL; CONCENTRATION LOSS; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DISEASE DURATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; FOOD; GENETIC MODEL; HUMAN; HYDROLYSIS; HYPESTHESIA; LATENT PERIOD; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; NAUSEA; NEURALGIA; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PATENT; PATIENT COMPLIANCE; PSYCHOSIS; RADIOACTIVITY; RECURRENT DISEASE; REVIEW; SEDATION; SEIZURE; SEX DIFFERENCE; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TONIC SEIZURE; TRAUMATIC BRAIN INJURY; VOMITING;

ANIMALS; ANTICONVULSANTS; CARBAMATES; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPILEPSY; HUMANS; PATENTS AS TOPIC;

EID: 34748917545     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. A receptor system. Ticku MK, Kamatchi GL, Sofia RD EPILEPSIA 1991 32 389-391
2. 300805 New IND for novel antiepileptic drug. SK Corp PRESS RELEASE 1998 October 07
3. 389973 SK and Janssen sign CNS drug deal. SK Corp PRESS RELEASE 2000 November 16
4. 405683 Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: Putative reactive metabolites of felbamate. Thompson CD, Kinter MT, MacDonald TL CHEM RES TOXICOL 1996 9 8 1225-1229
5. 490640 About us - company history. SK Bio-Pharmaceuticals COMPANY WORLD WIDE WEB SITE 2003 May 01
6. 540000 New antiepileptic drugs - Seventh Eilat Conference, Sardinia, Italy. Pitkanen A IDDB MEETING REPORT 2004 May 9-13
7. 576835 American Epilepsy Society - 58th Annual Meeting. Novel compounds for the treatment of seizures. Pitkanen A IDDB MEETING REPORT 2004 December 3-7
8. 583836 Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Bialer M, Johannessen SI, Kupferberg H, Levy RH, Perucca E, Tomson T EPILEPSY RES 2004 61 1-3 1-48
9. 600431 Current status and future directions in the pharmacotherapy of epilepsy. Loscher W TRENDS PHARMACOL SCI 2002 23 3 113-118
10. 616047 The use of chronic models in antiepileptic drug discovery: The effect of RWJ-333369 on spontaneous motor seizures in rats with kainate-induced epilepsy. Grabenstatter HL, Dudek FE EPILEPSIA 2004 45 Suppl 7 197
11. 640793 American Epilepsy Society - 59th Annual Meeting Joint with the American Clinical Neurophysiology Society (Part I). Pitkanen A IDDB MEETING REPORT 2005 December 2-6
12. 692334 New antiepileptic drugs - Eighth Eilat Conference (EILAT VIII). Perucca E A IDDB MEETING REPORT 2006 September 10-14
13. 743147 Diverse mechanisms of antiepileptic drugs in the development pipeline. Rogawski MA EPILEPSY RES 2006 69 3 272-294
14. 759611 NCT00425282: A study of the efficacy and safety of RWJ-333369 as add-on therapy in the treatment of partial onset seizures. ALZA Corp CLINICALTRIALS.GOV 2007 January 09
15. 771640 Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Chien S, Bialer M, Solanki B, Verhaeghe T, Doose DR, Novak G, Yao C EPILEPSIA 2006 47 11 1830-1840 • This paper presents results from a drug-drug interaction study with carisbamate and carbamazepine in healthy volunteers.
16. 771641 Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Yao C, Doose DR, Novak G, Bialer M EPILEPSIA 2006 47 1822-1829
17. 771643 The novel investigational neuromodulator RWJ-333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. White HS, Srivastava A, Klein B, Zhao B, Choi YM, Gordon R, Lee SJ EPILEPSIA 2006 47 Suppl 4 200-201
18. 771644 A new drug, RWJ-333369, protects limbic areas in the lithium-pilocarpine model (Li-Pilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures. Francois J, Ferrandon A, Koning E, Nehlig EPILEPSIA 2005 46 Suppl 8 269-270
19. 771645 A new drug, RWJ-333369 displays potent antiepileptic properties in genetic models of absence and audiogenic epilepsy. Nehlig A, Rigoulot MA, Boehrer A EPILEPSIA 2005 46 Suppl 8 215
20. 771646 RWJ-333369 pharmacokinetics are linear following single and repeated oral administration in healthy adult men. Yao C, Choi YM, Lee J, Doose DR, Novak G EPILEPSIA 2005 46 Suppl 8 192
21. 771647 Drug-drug interaction study between RWJ-333369 and carbamazepine in healthy adults. Chien SC, Yao C, Solanki B, Verhaeghe T, Doose D, Novak G EPILEPSIA 2005 46 Suppl 8 181
22. 771648 Lack of clinically significant pharmacokinetic drug interactions between RWJ-333369 and valproate or lamotrigine. Chien S, Yao C, Mertens A, Vertaeghe T, Solanki B, Doose D, Novak G EPILEPSIA 2005 46 Suppl 8 173
23. 771649 Epileptic outcome is correlated with protection in temporal cortices: Evidence from neuroprotection studies with a new drug, RWJ-333369, in the lithium-pilocarpine model. Francois J, Ferrandon A, Koning E, Nehlig A EPILEPSIA 2005 46 Suppl 8 62-63
24. 776702 Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII). Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T EPILEPSIA RES 2007 73 1 1-52
25. 792287 NCT00433667: A study of the efficacy and safety of RWJ-333369 as add-on therapy in the treatment of partial onset seizures. Johnson & Johnson Pharmaceutical Research & Development CLINICALTRIALS.GOV 2007 April 27
26. 792444 Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits and dogs. Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CGM, Kao M, Kelley MF, Meuldermans W DRUG METAB DISPOS 2007 35 4 566-575 • This paper presents an overview of the results of the metabolism and pharmacokinetics of carisbamate in animals.
27. 792456 The absorption, metabolism, and excretion of the novel neuron-modulator RWJ-333369 [1,2-ethanediol, (1-2-chlorophenyl)-, 2-carbamate, (S]-) in humans. Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B et al DRUG METAB DISPOS 2007 35 4 554-565 • This paper provides an overview of the results of the metabolism and pharmacokinetics of carisbamate in humans.
28. 793223 Pros and cons for the development of new antiepileptic drugs. Bialer M, Walker MC, Sander JW CNS Drugs 2002 16 5 285-289
29. 793366 Mechanism of action of antiepileptic drugs. Czapinski P, Blaszczyk B, Czuczwar SJ CURR TOP MED CHEM 2005 5 1 3-14
30. 793369 New anticonvulsant agents. Malawska B CURR TOP MED CHEM 2005 5 1 69-85
31. 793375 Target dose for evaluation of topiramate initiated as monotherapy. Pellock JM EPILEPSIA 2005 46 Suppl 8 215
32. 797523 The epidemiology of epilepsy: The size of the problem. Bell GS, Sander JW SEIZURE 2001 10 4 306-316
33. 797525 Medical treatment of epilepsy. Bauer J, Reuber M EXPERT OPIN EMERG DRUGS 2003 8 2 457-467
34. 797531 Felbamate block of recombinant N-methyl-D-aspartate receptors: Selectivity for the NR2B subunit. Harty TP, Rogawski MA EPILEPSY RES 2000 39 1 47-55
35. 798631 Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: An exploratory, placebo-controlled study. Trenite DG, French JA, Hirsch E, Macher JP, Meyer BU, Grosse PA, Abou-Khalil BW, Rosenfeld WE, van Gerven J, Novak GP, Parmeggiani L et al EPILEPSY RES 2007 74 2-3 193-200
36. 805412 Eisai launches Inovelon for Lennox-Gaustaut Syndrome. Eisai Co Ltd PRESS RELEASE 2007 June 18
37. 811879 US-06127412: Halogen-substituted carbamate compounds from 2-phenyl-1,2-ethanediol. Moon CY, Woo KM, Han PJ US PATENT 2000 October 03
38. 813832 NCT00501202: Study for safety and effectiveness of RWJ-333369 (carsibamate) for the treatment of diabetic peripheral neuropathy (DPN). Johnson & Johnson Pharmaceutical Research & Development LLC CLINICALTRIALS.GOV 2007 July 12
39. 813844 NCT00492323: An effectiveness and safety study with RWJ-333369 (carisbamate) for the study of postherpetic neuralgia (PHN). Johnson & Johnson Pharmaceutical Research & Development LLC CLINICALTRIALS.GOV 2007 June 29
40. 832038 An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, Novak G, Bialer M EPILEPSIA 2007 48 7 1328-1338
41. 832039 The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury. Keck CA, Thompson HJ, Pitkanen A, Lebold DG, Morales DM, Plevy JB, Puri R, Zhao B, Dichter M, McIntosh TK RESTORATIVE NEUROL NEUROSCI 2007 25 2 77-90